Celadon Pharmaceuticals
Cash Flow

Last updated:

Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Celadon Pharmaceuticals generated cash of -$5,972,000, which is more than the previous year. Cash used in financing activities reached the amount of $2,511,000 last year. Net change in cash is therefore -$3,802,000.

Cash Flow

Celadon Pharmaceuticals Plc (LSE:CEL.L): Cash Flow
2019 1.98K 0 5.82M
2020 -77.57K -697.03K 1.07M
2021 -3.14M -1.24M 7.91M
2022 -6.1M 1.39M 5.94M
2023 -5.97M -341K 2.51M

CEL.L Cash Flow Statement (2019 – 2023)

2023 2022 2021 2020 2019
Cash at beginning of period
5.06M3.82M300K1.48K-176.03K
Operating activities
Net income
-7.14M-17.41M-4.78M-1.05M-151.69K
Adjustments to reconcile net income to cash generated by operating activities:
Depreciation and amortization
534K466K319K160.84K33.48K
Stock-based compensation expense
285K7.31M000
Deferred income tax benefit 285K7.31M000
Changes in operating assets and liabilities:
Accounts receivable, net
108K-985K-2.13M5.89K-1.08K
Inventories
-6K-18K000
Accounts payable
-250K355K000
Cash generated by operating activities
-5.97M-6.1M-3.14M-77.57K1.98K
Investing activities
Purchases Of Investments
0-18K-200K00
Investments In Property Plant And Equipment
-341K-2.08M-542K-708.24K0
Acquisitions Net
03.49M-500K11.21K0
Cash generated by investing activities
-341K1.39M-1.24M-697.03K0
Financing activities
Common Stock Issued
2.97M7.49M389K1.02M5.82M
Payments for dividends
00000
Repurchases of common stock
00000
Repayments of term debt
-1K-1.51M-174K-50K0
Cash used in financing activities
2.51M5.94M7.91M1.07M5.82M
Net Change In Cash
-3.80M1.23M3.52M297.99K5.82M
Cash at end of period
1.25M5.06M3.82M299.47K5.64M
Data sourceData sourceData sourceData sourceData source